Company intelligence / Profile preview
ImageneBio
San Diego, California, United Statesinmagenebio.com ↗
- Ownership
- Public · IMA
- Development stage
- Other
01
Overview
IMG‑007, the lead program—a non-depleting anti-OX40 monoclonal antibody—has completed a Phase 2a trial in moderate-to-severe atopic dermatitis. The trial demonstrated marked and durable clinical activity with a well-tolerated safety profile. The company is now positioned to advance into later-stage development and potentially expand into other immunological indications.
- Therapeutic areas
- Dermatology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Partnerships
Deep Track CapitalForesite CapitalRTW InvestmentsBVF Partners L.P.Blue Owl Healthcare OpportunitiesOmega FundsOrbiMed
04
Financials
- Market cap
- $47.3M
- Total revenue
- $800K
- Enterprise value
- $-87M
Beyond the preview
Go deeper on ImageneBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImageneBio.